The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study

ConditionsDialysis; Complications Bleeding

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-99

SponsorWonju Severance Christian Hospital

About this trial

Comparison nafamostat and low molecular weight heparin among dialysis patients

Eligibility criteria

Qualifiers

platelet below 10k PTT above 60 second INR above 20 patient with bleeding (epistaxis, orbital bleeding, hematuria) recent brain hemorrhage (within 6 months) receiving anticoagulant therapy (coumadin or NOAC) dual antiplatelet agent users received major surgery within one month

Disqualifiers

cancer liver cirrhosis pregnancy drug allergy current bleeding on major organ (brain, gastrointestinal)

Trial design

Treatments tested in this trial

Nafamostat Mesylate

Treatment groups

100 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Wonju Severance Christian Hospital

Lead sponsor

Source ClinicalTrials.gov